Drugs / Multivalent Group B streptococcus vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04766086 | Aug 2022 → Apr 2023 | group B streptococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03170609 | Jun 2017 → Jun 2018 | group B streptococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07160244 | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-19 | Pfizer | Results Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate pfizer.com ↗
Results from an ongoing Phase 2 study in pregnant individuals showed the investigational vaccine, GBS6, was generally well-tolerated and generated robust maternal antibody responses that were efficiently transferred to infants |
| 2022-09-07 | Pfizer | Regulatory FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women pfizer.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multivalent group B streptococcus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03170609 ↗ |
| Known as | GBS6 | “investigational 6-valent GBS polysaccharide conjugate vaccine (GBS6)” PMID 40036340 ↗ Jul 20251“GBS conjugate vaccine (GBS6)” PMID 32891191 ↗ Sep 2020 |
| Modality | Vaccine | “GBS conjugate vaccine (GBS6)” PMID 32891191 ↗ Sep 2020 |
| Route | Intramuscular | “administered by intramuscular injection” PMID 32891191 ↗ Sep 2020 |